Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.

A Prospective, Open Label Trial of High Dose UVA-1, 3x/Week or Medium Dose UVA-1, 3x/Week vs. Fluocinonide 0.05% Cream Treatment of Morphea

Compare UVA-1 phototherapy treatment to topical steroid treatment in subjects with morphea.

Inclusion Criteria:

• Male and female subjects 18 years of age or older.
• Symmetric limited morphea.

Exclusion Criteria:

• Known sensitivity to fluocinonide 0.05% cream.
• Clinical evidence of superinfected skin.
• Immunocompromised state (including previously documented HIV).
• Generalized Scleroderma.
• Previous history of skin cancer.
• Non-English speaking subjects.